| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 92134 |
|
10,121 |
9,548 |
$931K |
| J0178 |
Injection, aflibercept, 1 mg |
1,445 |
1,402 |
$793K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
6,632 |
6,305 |
$635K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
1,096 |
1,050 |
$375K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
1,062 |
1,016 |
$114K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
1,254 |
1,246 |
$100K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
126 |
125 |
$88K |
| J7999 |
Compounded drug, not otherwise classified |
584 |
570 |
$12K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
100 |
100 |
$7K |
| 92250 |
|
101 |
101 |
$5K |
| J9035 |
Injection, bevacizumab, 10 mg |
28 |
28 |
$2K |
| 4177F |
|
144 |
142 |
$2K |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
822 |
799 |
$338.15 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
760 |
739 |
$0.00 |
| 1036F |
|
823 |
800 |
$0.00 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
144 |
142 |
$0.00 |